Cell therapy: A beacon of hope in the battle against pulmonary fibrosis
The FASEB Journal · 2025
DOI: 10.1096/fj.202402790r ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FASEB Journal, 2025. Verfasst von Ruyan Wan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell and Biotherapy Technology Research Center, School of Life Science and Technology, Xinxiang Medical University, Xinxiang, China. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Stem Cell Transplantation, Cell- and Tissue-Based Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 200 Literaturangaben. Gefördert von: Natural Science Foundation of Henan Province (Henan Natural Science Foundation), Doctoral Research Start Up Fund.
Abstract (Originalsprache)
Pulmonary fibrosis (PF) is a chronic and progressive interstitial lung disease characterized by abnormal activation of myofibroblasts and pathological remodeling of the extracellular matrix, with a poor prognosis and limited treatment options. Lung transplantation is currently the only approach that can extend the life expectancy of patients; however, its applicability is severely restricted due to donor shortages and patient‐specific limitations. Therefore, the search for novel therapeutic strategies is imperative. In recent years, stem cells have shown great promise in the field of regenerative medicine due to their self‐renewal capacity and multidirectional differentiation potential, and a growing body of literature supports the efficacy of stem cell therapy in PF treatment. This paper systematically summarizes the research progress of various stem cell types in the treatment of PF. Furthermore, it discusses the primary methods and clinical outcomes of stem cell therapy in PF, based on both preclinical and clinical data. Finally, the current challenges and key factors to consider in stem cell therapy for PF are objectively analyzed, and future directions for improving this therapy are proposed, providing new insights and references for the clinical treatment of PF patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Stem Cell and Biotherapy Technology Research Center, School of Life Science and Technology, Xinxiang Medical University, Xinxiang, China.
- Henan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Xinxiang, China.
- Henan Joint International Research Laboratory of Stem Cell Medicine, School of Biomedical Engineering, Xinxiang Medical University, Xinxiang, China.
ORCID-Profile: Ruyan Wan, Yanli Liu, Jingwen Yan, Juntang Lin
Förderung
- Natural Science Foundation of Henan Province (Henan Natural Science Foundation)
- Doctoral Research Start Up Fund
Zitieren
APA
Wan, R., Liu, Y., Yan, J., & Lin, J. (2025). Cell therapy: A beacon of hope in the battle against pulmonary fibrosis. The FASEB Journal. https://doi.org/10.1096/fj.202402790r
Vancouver
Wan R, Liu Y, Yan J, Lin J. Cell therapy: A beacon of hope in the battle against pulmonary fibrosis. The FASEB Journal. 2025. doi:10.1096/fj.202402790r
BibTeX
@article{Wan2025,
author = {Wan, Ruyan and Liu, Yanli and Yan, Jingwen and Lin, Juntang},
title = {Cell therapy: A beacon of hope in the battle against pulmonary fibrosis},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202402790r}
}
EUVIMED